Granted Patent B2

US 12,251,336 · App. 17/393,059 · Granted Mar 18, 2025

Inventors: Bradley G. Bachelder (South San Francisco, CA); Randolph E. Campbell (Redwood City, CA); Darren Doud (Los Altos, CA); Signe Erickson (South San Francisco, CA); Kevin W. Sacherman (Palo Alto, CA)

Assignee: ForSight Vision4, Inc.

A61F9/0017A61K9/0051A61F2210/0014A61F2210/0061A61F2250/001A61F2250/0068A61F2250/0069

Abstract

Claims (36)

1. A drug delivery device configured to be at least partially implanted in an eye, the device comprising:

a retention structure positioned near a proximal end region of the device;

a porous drug release element positioned in fluid communication with an outlet of the device;

an elongated core element having a longitudinal axis extending from a proximal end of the elongated core element to a distal end of the elongated core element; and

a reservoir wall positioned around and eccentric to the longitudinal axis of the elongated core element, the reservoir wall defining a reservoir volume configured to contain one or more therapeutic agents, the reservoir volume in fluid communication with the outlet through the porous drug release element,

wherein the reservoir wall is configured to transition from an insertion configuration having a first three-dimensional shape to a deployed configuration having a second three-dimensional shape such that the second three-dimensional shape is eccentrically positioned relative to the longitudinal axis of the elongated core element.

2. The device of claim 1 , wherein a first portion of the reservoir volume in the deployed configuration is directed away from the lens of the eye and is greater than a remaining portion of the reservoir volume.

3. The device of claim 2 , wherein the first portion and the remaining portion of the reservoir volume each remain outside the visual axis of the eye.

4. The device of claim 1 , wherein a proximal end of the reservoir wall is separated a distance from one or more internal tissue surfaces surrounding a penetration site of the eye when in the deployed configuration.

5. The device of claim 1 , wherein the elongated core element extends from the proximal end region of the device to a distal end region of the device.

6. The device of claim 5 , wherein the drug release element is coupled to the elongated core element near the distal end region of the device and the retention structure is coupled to the elongated core element near the proximal end region of the device.

7. The device of claim 5 , wherein the elongated core element comprises an inner lumen and one or more openings extending through the elongated core element, wherein the inner lumen of the elongated core element is in fluid communication with the reservoir volume through the one or more openings.

8. The device of claim 7 , wherein the elongated core element comprises a cylindrical geometry and further comprises a flow director to direct flow through the one more openings.

9. The device of claim 8 , wherein the flow director comprises a first cylindrical region coupled to a second cylindrical region by a funnel shaped region, wherein the first cylindrical region has a larger cross-sectional diameter than the second cylindrical region.

10. The device of claim 5 , wherein the retention structure comprises a proximal flange element configured to extend outside a sclera of the eye and a neck, the neck having a proximal region configured to extend through a penetration site in the sclera of the eye and a distal extension extending inside the vitreal cavity of the eye.

11. The device of claim 10 , wherein the distal extension of the neck surrounds a portion of the elongated core element near the proximal end of the device providing stabilization of the neck to maintain a position of the reservoir wall.

12. The device of claim 11 , wherein the distal extension of the neck prevents contact between the reservoir wall and internal surfaces of the eye adjacent the penetration site.

13. The device of claim 11 , wherein an upper surface of the proximal flange element indicates orientation of the reservoir wall in the deployed configuration and a direction of eccentricity of the second three-dimensional shape.

14. The device of claim 13 , wherein the upper surface indicates orientation due to a shape of the flange element or a mark on the upper surface of the flange element visible to a user from outside the eye.

15. A method of treating an eye with an implantable drug delivery device, the method comprising:

implanting a distal end region of a device into a vitreal cavity of an eye, the distal end region comprising:

a porous drug release element positioned in fluid communication with an outlet of the device;

a rigid elongated core element having a longitudinal axis; and

a reservoir having a volume in fluid communication with the outlet through the porous drug release element, the volume of the reservoir positioned around at least a middle region of the elongated core element and asymmetric to the longitudinal axis;

positioning a proximal end region of the device comprising a retention structure outside a sclera of the eye; and

injecting into the reservoir a drug formulation comprising one or more therapeutic agents, wherein injecting the drug formulation into the reservoir unfolds the reservoir from an insertion configuration to a deployed configuration, the deployed configuration being asymmetrical relative to the elongated core element.

16. The method of claim 15 , further comprising facilitating filling of the reservoir with the drug formulation with a flow director positioned within a lumen of the elongated core element.

17. The method of claim 16 , wherein the flow director comprises a first cylindrical region coupled to a second cylindrical region by a funnel-shaped region to direct flow through one or more openings in the elongated core element, wherein the first cylindrical region has a larger cross-sectional diameter than the second cylindrical region.

18. The method of claim 15 , further comprising forming a major portion of the reservoir relative to the elongated core element and a minor portion relative to the elongated core element as the reservoir unfolds asymmetrically.

19. The method of claim 18 , wherein unfolding of the reservoir into the deployed configuration inside the eye directs the major portion away from anterior tissue of the vitreal cavity of the eye.

20. The method of claim 15 , wherein the retention structure comprises a proximal flange element extending outside the sclera of the eye and a neck, the neck having a proximal region extending through a penetration site in the sclera of the eye and a distal extension extending inside the sclera of the eye.

21. The method of claim 20 , further comprising stabilizing the neck to maintain a position of the reservoir with the distal extension of the neck surrounding a portion of the elongated core element near the proximal end of the device.

22. The method of claim 21 , further comprising preventing contact between the reservoir and internal surfaces of the eye adjacent the penetration site with the distal extension of the neck.

23. The method of claim 15 , wherein the one or more therapeutic agents are selected from the group consisting of bimatoprost, latanoprost, ranibizumab, travoprost, timolol, levobunaolol, brimonidine, dorzolamide, and brinzolamide.

24. The method of claim 15 , wherein the one or more therapeutic agents are used to treat a condition selected from the group consisting of glaucoma, dry or wet age-related macular degeneration, neuroprotection of retinal ganglion cells, cataract or presbyopia prevention, cancers, angiogenesis, neovascularization, choroidal neovascularization (CNV) lesions, retinal detachment, proliferative retinopathy, proliferative diabetic retinopathy, degenerative disease, vascular diseases, occlusions, infection, endophthalmitis, posterior uveitis, retinitis, choroiditis, tumors, and retinoblastoma.

25. The method of claim 15 , wherein the reservoir contains a fluid volume of up to about 100 ul.

Assignments (1)

Continuity (4)

References Cited (400)